Session: SUN 257-280-Disorders of Vitamin D Metabolism & Action
Poster Board SUN-270
Methods: All subjects applying to our clinic between December 2011 and February 2012 for whom 25 OH vitamin D3 (25OHD3) levels measured for any reason were included to this cross-sectional study. Those with a history of diabetes mellitus, impaired glucose tolerance, laboratory findings of renal or hepatic dysfunction, a coagulation disorder, atherosclerotic disease, and those of any form of medication effect on coagulation parameters were excluded. Coagulation parameters were measured including prothrombin time (PTT), activated partial thromboplastin time (aPTT), D-dimer, fibrinogen, homocysteine, tissue factor pathway inhibitor (TFPI), thrombomodulin, and tissue plasminogen activator (t-PA). Patients were divided into 3 groups based on levels of 25OHD3 as Group 1 (25OHD3< 10 ng/mL, n= 25), Group 2 (25OHD3=10-19.9 ng/mL, n=22) , and Group 3 (25OHD3≥20 ng/mL, n=28).
Results: A total of 75 patients mean aged 39 (range; 18-57) years were included in the study. Age, body mass index and sex were similar between groups (p>0.05). PTT was longer in group 3 than group 2 (p=0.043). Tęssue factor pathway inhibitor levels were higher in patients in group 3 compared to the other groups (p<0.0001). The correlation analyses were performed and it was found a strong positive correlation between 25OHD3 and TFPI levels (r=0.47, p<0.0001). There was no significant correlation between 25OHD3 and other coagulation parameters.
Conclusion: TFPI is a major inhibitor of coagulation. We demonstrated lower TFPI values in patients with 25OHD3 levels less than 20 ng/mL. Coagulation parameters indicate that the patients with low vitamin D levels are more prone to thrombosis. Therefore, more attention should be focused on vitamin D deficiency and this needs to be investigated in prospective studies. The change in coagulation parameters with vitamin D treatment should be also evaluated in further studies.
Nothing to Disclose: OT, MS, MK, BU, ZG, EC, TD, MS, MO, EC, TD
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters